Breaking News

Tweet TWEET

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) updates on four early clinical trials with IPH2101 in Multiple Myeloma

PR Newswire/Les Echos/ 
PRESS RELEASE 
                        UPDATE ON CLINICAL TRIALS  
                     WITH IPH2101 IN MULTIPLE MYELOMA 
Marseilles, France, December 11, 2012
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), the
innate immunity company developing first-in-class drugs for cancer and
inflammatory diseases, updates on four early clinical trials with IPH2101
(hybridoma anti-KIR antibody) in Multiple Myeloma ("MM"). 
- Interim data of Phase I trial KIRIMID presented at ASH: a poster describing
interim data from the Phase I study KIRIMID, investigating the safety and
tolerability of the combination of IPH2101 with lenalidomide in patients with
relapsed MM following one or two lines of prior therapy was presented at the
2012 American Society of Hematology ("ASH") meeting by Don Benson, MD, PhD
(Division of Hematology/ Oncology, Ohio State Cancer Center, Columbus, OH). 
The poster is available on Innate Pharma's 
website: http://www.innatepharma.com/sites/default/files/ash_2012_
antikir_and_lena_phase_1_poster.pdf. 
- Publication of Phase I results of IPH2101 in MM in Blood: the results of the
Phase I trial of IPH2101 in 32 patients with relapsed/refractory MM were
published online in the journal Blood. Patients were treated with IPH2101 for 
up to 4 cycles without achieving dose-limiting toxicity (DLT) or reaching 
maximal tolerated dose (MTD). Analysis of PK data demonstrated a clear 
relationship between dose and drug concentration. 
Innate Pharma also reports the results of the Phase IIa trials REMYKIR and
KIRMONO. IPH2101, tested as a single agent in patients with stable measurable 
MM after induction therapy (REMYKIR study) and in patients with previously
untreated smoldering myeloma (KIRMONO study), did not show significant
reductions in M-protein levels, the primary efficacy endpoint of the studies.
The safety profile of IPH2101 was satisfactory. 
Marcel Rozencweig, Executive Vice President and Chief Medical Officer of 
Innate Pharma, said: "These published data were obtained with our first 
generation anti-KIR antibody. IPH2102/BMS-986015 is a second generation 
anti-KIR antibody that has been selected for further development and patients 
are now being treated with IPH2102 in the recently announced Phase II 
single-agent trial in Acute Myeloid Leukemia and the Phase I combination trial 
with the Anti-PD-1 antibody nivolumab in solid tumors." 
About IPH2101: 
IPH2101 is an anti-KIR monoclonal antibody, produced in hybridoma cell lines,
which has been developed and tested in an early development plan for the IPH21
program. 
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases. 
The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by licence agreements with 
two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb. 
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate 
Pharma is based in Marseilles, France, and had 81 employees as at 
September 30, 2012. 
Learn more about Innate Pharma at www.innate-pharma.com.  
Practical Information about Innate Pharma shares: 
ISIN code           FR0010331421
Ticker code         IPH 
Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ 
from those contained in the forward-looking statements, please refer to the 
Risk Factors ("Facteurs de Risque") section of the Document de Reference 
prospectus filed with the AMF, which is available on the AMF website 
(http ://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country. 
For additional information, please contact: 
Innate Pharma                   ATCG Press
Laure-Hélène Mercier            Marielle Bricman
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87     Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com     mb@atcg-partners.com  
121211 Update on trials with IPH2101 
                  
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Dec/11/2012 07:57 GMT